<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2044">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01487395</url>
  </required_header>
  <id_info>
    <org_study_id>2010_41</org_study_id>
    <secondary_id>2010-023989-51</secondary_id>
    <nct_id>NCT01487395</nct_id>
  </id_info>
  <brief_title>Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development</brief_title>
  <acronym>PharmacogWP3</acronym>
  <official_title>Effect of a 15-day Donepezil Treatment on Biomarkers of AD in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovative Medicines Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The early assessment of new drugs for Alzheimer's disease remains difficult because of the&#xD;
      lack of predictive end-point. The use of a battery including different parameters could&#xD;
      improve this early development of new drugs. Nevertheless, the interest of such a battery&#xD;
      should previously be validated with the yet marketed AD drugs&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the present study is to test the effect of a 15-day treatment with donepezil on a&#xD;
      mixed battery associating cognitive assessment, imaging and neurophysiological tests in&#xD;
      healthy volunteers.&#xD;
&#xD;
      This multicenter, randomized, placebo-controlled, cross-over study is double-blind controlled&#xD;
      and is conducted in 3 centers located in France (Lille, Marseille and Toulouse).&#xD;
&#xD;
      18-30 years old, healthy volunteers, without any neurological or psychiatric impairment, will&#xD;
      complete 2 test sessions in a randomized order: one with a 15-day treatment with donepezil,&#xD;
      the other with placebo, and will be submitted to a mixed battery during the 14th and 15th day&#xD;
      of the treatment. The primary outcome of the study will be based on cognitive assessment,&#xD;
      imaging parameters and neurophysiological parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacog battery</measure>
    <time_frame>15 days</time_frame>
    <description>cognitive tests (8 items of the Cantab battery) :&#xD;
Motor screening&#xD;
4 tests for visual memory (Delayed Matching to Sample, Paired Associated Learning, Pattern Recognition Memory, Spatial Recognition Memory)&#xD;
1 test for executive functions (Spatial Working Memory)&#xD;
2 tests for attention (Reaction Time, Rapid Visual Information Processing)&#xD;
completed by a modified ADNI battery : ADAScog&#xD;
imaging&#xD;
fMRI&#xD;
PET-FDG&#xD;
neurophysiological&#xD;
EEG</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Battery</condition>
  <arm_group>
    <arm_group_label>Donepezil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo will be presented as tablet comparable to ARICEPT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil .</intervention_name>
    <description>Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.</description>
    <arm_group_label>Donepezil</arm_group_label>
    <other_name>ARICEPT ® Donépezil</other_name>
    <other_name>Orally Disintegrating Tablets (ODT): 5 mg.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>the placebo will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-30 year old male non-smoker subjects&#xD;
&#xD;
          -  Subject without cognitive impairment or cognitive complaint (Moca&gt;26, Mac Nair&#xD;
             scale&lt;15)&#xD;
&#xD;
          -  Subject without history of brain disease (severe brain trauma, stroke, cerebral&#xD;
             tumor,…)&#xD;
&#xD;
          -  Subject without major medical or surgical history&#xD;
&#xD;
          -  Subject without current chronic disease&#xD;
&#xD;
          -  Subject without current cerebral disease&#xD;
&#xD;
          -  Subject without vascular or metabolic risk factor&#xD;
&#xD;
          -  Subject without history or current mental disease or addiction (MINI)&#xD;
&#xD;
          -  Subject without lesion on MRI&#xD;
&#xD;
          -  Subject without abnormal electrical activities on EEG&#xD;
&#xD;
          -  Subject without use of chronic treatment or psychotropic drugs or substances&#xD;
&#xD;
          -  French speaker subject and able to understand the test instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with age &lt; 18 years or &gt; 30 years&#xD;
&#xD;
          -  Subject with dementia or cognitive decline identified by Moca &lt; 26&#xD;
&#xD;
          -  Subject with history of brain disease (brain trauma, stroke, cerebral tumor,…)&#xD;
&#xD;
          -  Subject with major medical or surgical history&#xD;
&#xD;
          -  Subject with current chronic disease&#xD;
&#xD;
          -  Subject with current cerebral disease&#xD;
&#xD;
          -  Subject with vascular or metabolic risk factor&#xD;
&#xD;
          -  Subject with history or current mental disease or addiction&#xD;
&#xD;
          -  Subject with family history of young-onset dementia&#xD;
&#xD;
          -  Subject with family history of chronic or severe neurological or mental disease (first&#xD;
             degree relatives)&#xD;
&#xD;
          -  Subject with lesion on MRI&#xD;
&#xD;
          -  Subject with abnormal electrical activities on EEG&#xD;
&#xD;
          -  Subject receiving a chronic treatment&#xD;
&#xD;
          -  Subject using chronically or acutely psychotropic drugs or substances&#xD;
&#xD;
          -  Subject with claustrophobia or contra-indication to MRI&#xD;
&#xD;
          -  Subject unable to understand the test instructions&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Régis Bordet, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU de Lille/ Centre d'investigation Clinique</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIC Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIC Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>December 5, 2011</study_first_submitted>
  <study_first_submitted_qc>December 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2011</study_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer</keyword>
  <keyword>Donepezil</keyword>
  <keyword>biomarkers</keyword>
  <keyword>battery</keyword>
  <keyword>cognition</keyword>
  <keyword>imaging</keyword>
  <keyword>neurophysiological</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

